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Translational Research Project: 




1. Cyclic GMP-Dependent Pathway as a 
Tumor Suppressor System to Prevent 
Colorectal Tumorigenesis 
 
2.   Cyclic GMP-Dependent Pathway as an 
Antimetastatic Strategy to Disrupt 
Colorectal Cancer Metastatic Progression 
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General Model for cGMP Signaling 
Cyclic GMP Signaling 
Tiyyagura, S.R. et al.  (2004) Vit. Hormones 69:69-94 
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Curr. Topics Biochem. Res. 5:181-92 
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GCC is selectively 
expressed at brush-
border membranes of 
intestinal epithelial cells 
and regulates fluid 
homeostasis 
Crypt and Villus 
Enterocytes 
Gartner L.P. (1997) Williams & Wilkins Pub. Co., Baltimore 
and Hiatt, J.L. Color Textbook of Histology  
Guanylyl Cyclase C (GCC) 
Pitari, G.M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:2695-99 
Antiproliferative cGMP Signaling Targets 

































































Antiproliferative cGMP Signaling 
Undergoes Negative Feedback 
Regulation 






















The Antiproliferative cGMP Signaling 
Pathway in Intestinal Epithelial Cells 











Cyclic GMP Signaling by GCC Controls 
The Crypt-Villus Homeostasis 
Pitari, G.M. et al. (2007) 
 Clin. Pharmacol. Ther. 82:441-7 
Colon Cancer: the 2nd Most Deadly 
Cancer in Developed Nations  
The Pathological Sequence 
of Colorectal Cancer 
Adenomatous Polyps 
Aberrant Crypt Foci 









































Invasion of the serosa 





Invasion up to the  
muscularis propria 
 




~ 95%  ~ 80%  ~ 65%  ~ 7% 
Pitari, G.M. et al.  (2003) 
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ETEC Infections Confer 
Resistance to Colon Cancer 
GCC is a Therapeutic Target 
in Colon Cancer 
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GCC is a Novel Intestinal 
Tumor Suppressor 
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* * * 
Pitari, G.M. et al.  (2008) 
Carcinogenesis 29:1601-7 
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GCC Regulates the Function 
of Calcium-Sensing Receptor 
(CaR) in the Intestine 















































* * * 
Control 
GCC-Targeted Therapy 
in Combination with 
Dietary Calcium 















A Tumor Suppressor cGMP Signaling 
Pathway in Colon Cancer 
Pitari, G.M. et al.  (2008) 
Carcinogenesis 29:1601-7 
Colon Cancer Mortality Reflects 
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Cyclic GMP Induces Functional 
Remodeling of Cancer Cell MMP-9 





















































































































































































































































Pro-MMP-9 - 92 kDa 
Cell CM 
T84 
Lubbe, W.J. et al. (2006) Clin. Cancer Res. 12:1876-82 
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Lubbe, W.J. et al. (2006) Clin. Cancer Res. 12:1876-82 
DIC DAPI MMP-9 β-Actin Merge 
PBS 


























































Lubbe, W.J. et al. (2009) 
Cancer Res. On Line First 
GCC and cGMP Signaling through 
MMP-9 Regulates Colon Cancer Cell 
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GCC and cGMP Signaling through 
MMP-9 Suppresses Metastatic 















The Antimetastatic cGMP Signaling 
Pathway in Colon Cancer Cells 
Lubbe, W.J. et al. (2009) Cancer Res. On Line First 
(-) cGMP Pathway (+) cGMP Pathway 
Summary  
•The cGMP pathway reduces the metastatic potential of colorectal cancer 
cells, in vitro and in vivo, in part by regulating the function of MMP-9 
 
•The cGMP pathway in intestinal epithelial cells regulates the 
crypt-villus axis and opposes colorectal tumorigenesis 
 
•Cancer cell MMP-9 regulates metastatic functions, including actin 
polymerization and cell spreading, and in vivo seeding of target organs 
•GCC, a guanylyl cyclase receptor selectively expressed by 
normal and malignant intestinal epithelial cells, coordinates a 
paracrine tumor suppressor system in the intestine 
•The cGMP pathway potentiates the cytostatic effects of extracellular 
calcium by regulating the activity of CaR 
 
Translational Significance 
• GCC ligands represents novel agents for the 
prevention of primary and metastatic colon cancer 
• GCC ligands represents novel agents for the 
treatment of primary and metastatic colon cancer 
• Cancer cell MMP-9 is a highly selective and 
effective molecular target for preventing 
metastatic progression of colorectal cancer 
• Combinatorial strategies with GCC ligands and 
dietary calcium may provide a novel paradigm for 
the treatment of colon cancer 
